HK1041262B - 吲衍生物 - Google Patents

吲衍生物 Download PDF

Info

Publication number
HK1041262B
HK1041262B HK02102830.8A HK02102830A HK1041262B HK 1041262 B HK1041262 B HK 1041262B HK 02102830 A HK02102830 A HK 02102830A HK 1041262 B HK1041262 B HK 1041262B
Authority
HK
Hong Kong
Prior art keywords
indol
palladium
ylmethyl
reaction
mixture
Prior art date
Application number
HK02102830.8A
Other languages
English (en)
Chinese (zh)
Other versions
HK1041262A1 (en
Inventor
Y. Chen Cheng
D. Larsen Robert
R. Verhoeven Thomas
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of HK1041262A1 publication Critical patent/HK1041262A1/xx
Publication of HK1041262B publication Critical patent/HK1041262B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Inorganic Insulating Materials (AREA)
HK02102830.8A 1994-05-24 2002-04-15 吲衍生物 HK1041262B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/248,288 US5567824A (en) 1994-05-24 1994-05-24 Palladium catalyzed ring closure of triazolyltryptamine
US248,288 1994-05-24

Publications (2)

Publication Number Publication Date
HK1041262A1 HK1041262A1 (en) 2002-07-05
HK1041262B true HK1041262B (zh) 2005-04-15

Family

ID=22938473

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02102830.8A HK1041262B (zh) 1994-05-24 2002-04-15 吲衍生物

Country Status (24)

Country Link
US (1) US5567824A (en:Method)
EP (1) EP0763032B1 (en:Method)
JP (1) JP3947216B2 (en:Method)
KR (1) KR100385027B1 (en:Method)
CN (2) CN1157390C (en:Method)
AT (1) ATE252095T1 (en:Method)
AU (1) AU688505B2 (en:Method)
DE (1) DE69531939T2 (en:Method)
DK (1) DK0763032T3 (en:Method)
ES (1) ES2207648T3 (en:Method)
FI (1) FI116899B (en:Method)
HK (1) HK1041262B (en:Method)
HR (1) HRP950304B1 (en:Method)
HU (1) HU226460B1 (en:Method)
MX (1) MX9605838A (en:Method)
NZ (1) NZ285539A (en:Method)
PT (1) PT763032E (en:Method)
RO (1) RO118586B1 (en:Method)
RU (1) RU2138496C1 (en:Method)
SK (1) SK284495B6 (en:Method)
TW (1) TW300221B (en:Method)
UA (1) UA52586C2 (en:Method)
WO (1) WO1995032197A1 (en:Method)
YU (1) YU49345B (en:Method)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA965837B (en) * 1995-07-11 1997-01-31 Merck & Co Inc A triazolylmethyl-indole ethylamine bisulfate salt
EP0840733B1 (en) * 1995-07-11 2001-10-24 Merck & Co., Inc. A triazolylmethyl-indole ethylamine bisulfate salt
US5877329A (en) * 1996-08-13 1999-03-02 Merck & Co., Inc. Palladium catalyzed indolization
US5811551A (en) * 1996-08-13 1998-09-22 Merck & Co., Inc. Palladium catalyzed indolization
AU4053497A (en) * 1996-08-13 1998-03-06 Merck & Co., Inc. Palladium catalyzed indolization
US5808064A (en) * 1996-08-13 1998-09-15 Merck & Co., Inc. Palladium catalyzed indolization
EP1400519B1 (en) * 1999-06-28 2007-03-07 Janssen Pharmaceutica N.V. Respiratory syncytial virus replication inhibitors
ES2204303B2 (es) * 2002-08-07 2004-12-16 Laboratorios Vita, S.A. Procedimiento para la obtencion de un compuesto farmaceuticamente activo.
EP1709032A2 (en) 2004-01-09 2006-10-11 Ratiopharm GmbH Crystalline forms of rizatriptan benzoate
ATE461916T1 (de) * 2004-01-28 2010-04-15 Ratiopharm Gmbh Syntheseverfahren und zwischenprodukte zur herstellung von rizatriptan
PA8626701A1 (es) * 2004-03-26 2006-05-16 Wyeth Corp Procedimientos para la preparacion de compuestos aminoarilos yodados
WO2006082598A2 (en) * 2005-02-01 2006-08-10 Natco Pharma Limited Novel crystalline forms of rizatriptan benzoate
WO2006137083A1 (en) * 2005-06-20 2006-12-28 Natco Pharma Limited Improved process for the preparation of rizatriptan benzoate
EP1951713A1 (en) * 2005-11-14 2008-08-06 Matrix Laboratories Ltd Process for the large scale production of rizatriptan benzoate
US20110313171A1 (en) * 2006-01-19 2011-12-22 Chandra Purna Ray Conversion of aromatic diazonium salt to aryl hydrazine
AU2008259518A1 (en) * 2007-06-04 2008-12-11 Generics [Uk] Limited Novel process
CA3010568C (en) 2016-01-27 2023-10-17 Instar Technologies A.S. Oromucosal nanofiber carriers for therapeutic treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
CA2084531A1 (en) * 1991-12-19 1993-06-20 David W. Smith Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines
GB9215526D0 (en) * 1992-07-22 1992-09-02 Merck Sharp & Dohme Chemical process

Also Published As

Publication number Publication date
PT763032E (pt) 2004-02-27
ATE252095T1 (de) 2003-11-15
YU33495A (sh) 1998-07-10
HRP950304A2 (en) 1997-08-31
WO1995032197A1 (en) 1995-11-30
ES2207648T3 (es) 2004-06-01
CN1152920A (zh) 1997-06-25
EP0763032B1 (en) 2003-10-15
CN1157390C (zh) 2004-07-14
SK284495B6 (sk) 2005-05-05
CN1322725A (zh) 2001-11-21
NZ285539A (en) 1998-06-26
AU688505B2 (en) 1998-03-12
FI964669A0 (fi) 1996-11-22
FI964669L (fi) 1996-11-22
JPH10500680A (ja) 1998-01-20
KR100385027B1 (ko) 2003-08-14
YU49345B (sh) 2005-07-19
DK0763032T3 (da) 2004-02-09
AU2467195A (en) 1995-12-18
CN1077104C (zh) 2002-01-02
FI116899B (fi) 2006-03-31
HUT76469A (en) 1997-09-29
HK1041262A1 (en) 2002-07-05
HU226460B1 (en) 2008-12-29
SK149896A3 (en) 1997-09-10
EP0763032A1 (en) 1997-03-19
US5567824A (en) 1996-10-22
DE69531939T2 (de) 2004-07-29
JP3947216B2 (ja) 2007-07-18
TW300221B (en:Method) 1997-03-11
RO118586B1 (ro) 2003-07-30
MX9605838A (es) 1997-12-31
DE69531939D1 (de) 2003-11-20
HK1009045A1 (en) 1999-05-21
RU2138496C1 (ru) 1999-09-27
UA52586C2 (uk) 2003-01-15
KR970703336A (ko) 1997-07-03
HRP950304B1 (en) 2004-12-31
HU9603236D0 (en) 1997-01-28

Similar Documents

Publication Publication Date Title
CN1157390C (zh) 吲哚衍生物
CN1053190C (zh) 新的喹喔啉二酮衍生物、其制备方法和作为药物的应用
CN1137103C (zh) 制备三唑啉硫酮衍生物的方法
CN85104233A (zh) 化学化合物
CN1688556A (zh) 缬沙坦的制备方法
CN1217930C (zh) 吲哚衍生物的制备方法和该方法的中间体
CN1083430C (zh) 咔唑酮衍生物
JP2013525413A (ja) ルフィナマイド中間体の改良された製造方法
CN1636988A (zh) 芳基醚的制备方法
CN1890213A (zh) 制备n－氨基取代的杂环化合物的方法
CN1671669A (zh) 二芳基吡唑的合成方法
CN1095830C (zh) 制备烷氧基亚氨基乙酰胺衍生物的方法
CN1668599A (zh) 用于制备喹诺酮抗生素中间体的方法
CN1922193A (zh) 化学方法
CN1620425A (zh) 制备氨基甲酸2－(取代苯基)－2－羟基－乙酯的方法
CN1045780A (zh) 新磺酰胺衍生物的制备
CN1360574A (zh) 制备三环氨基醇衍生物的方法
CN1400976A (zh) 吲哚吡咯并咔唑衍生物的制备方法、制备中的中间体以及制备中间体的方法
CN1109051A (zh) 3-(苯烷胺基烷氧基)-5-苯基吡唑、制法、中间体及药物
CN1678601A (zh) 由粘卤酸制备官能化的γ－丁内酯的方法
HK1009045B (en) Palladium catalyzed ring closure of triazolyl tryptamine
CZ296249B6 (cs) Zpusob výroby triazolyltryptaminového derivátu
HK1032588A (en) Method for producing triazolinthion derivatives
CN1095062A (zh) 取代的吡咯烷-2-酮的纯对映异构体制备方法
HK1032592A (en) Method for producing triazolinthion derivatives

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20150518